JP6765364B2 - ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド - Google Patents

２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド Download PDF

Info

Publication number
JP6765364B2
JP6765364B2 JP2017508531A JP2017508531A JP6765364B2 JP 6765364 B2 JP6765364 B2 JP 6765364B2 JP 2017508531 A JP2017508531 A JP 2017508531A JP 2017508531 A JP2017508531 A JP 2017508531A JP 6765364 B2 JP6765364 B2 JP 6765364B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
reaction
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525699A (ja
JP2017525699A5 (enExample
Inventor
マイケル オニール ハンラハン クラーク，
マイケル オニール ハンラハン クラーク，
リチャード エル． マックマン，
リチャード エル． マックマン，
ダスティン シーゲル，
ダスティン シーゲル，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド, ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2017525699A publication Critical patent/JP2017525699A/ja
Publication of JP2017525699A5 publication Critical patent/JP2017525699A5/ja
Application granted granted Critical
Publication of JP6765364B2 publication Critical patent/JP6765364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017508531A 2014-08-21 2015-08-19 ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド Active JP6765364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040349P 2014-08-21 2014-08-21
US62/040,349 2014-08-21
PCT/US2015/045849 WO2016028866A1 (en) 2014-08-21 2015-08-19 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020070958A Division JP2020111608A (ja) 2014-08-21 2020-04-10 ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド

Publications (3)

Publication Number Publication Date
JP2017525699A JP2017525699A (ja) 2017-09-07
JP2017525699A5 JP2017525699A5 (enExample) 2018-09-06
JP6765364B2 true JP6765364B2 (ja) 2020-10-07

Family

ID=54066190

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017508531A Active JP6765364B2 (ja) 2014-08-21 2015-08-19 ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド
JP2020070958A Withdrawn JP2020111608A (ja) 2014-08-21 2020-04-10 ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020070958A Withdrawn JP2020111608A (ja) 2014-08-21 2020-04-10 ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド

Country Status (17)

Country Link
US (6) US9617295B2 (enExample)
EP (2) EP3183261B1 (enExample)
JP (2) JP6765364B2 (enExample)
KR (1) KR102528928B1 (enExample)
CN (1) CN106573954A (enExample)
AR (1) AR101561A1 (enExample)
AU (1) AU2015305593C1 (enExample)
BR (1) BR112017003242A2 (enExample)
CA (1) CA2958546C (enExample)
EA (1) EA201790234A1 (enExample)
ES (1) ES2808868T3 (enExample)
IL (1) IL250426A0 (enExample)
MX (1) MX2017002288A (enExample)
NZ (1) NZ728707A (enExample)
SG (1) SG11201700810SA (enExample)
TW (1) TWI673283B (enExample)
WO (1) WO2016028866A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TWI673283B (zh) * 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
PE20170698A1 (es) * 2014-09-26 2017-06-05 Riboscience Llc Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
WO2018009623A1 (en) * 2016-07-08 2018-01-11 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
US20250009777A1 (en) * 2021-11-12 2025-01-09 National University Corporation Hokkaido University Antiviral agent
TW202400134A (zh) 2022-03-15 2024-01-01 美商羅米醫療公司 用於治療疾病之化合物及方法
WO2024016639A1 (zh) * 2022-07-21 2024-01-25 华创合成制药股份有限公司 一种抗病毒感染的化合物及其制备方法和用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
CA2112674C (en) 1991-07-02 2005-10-04 John S. Patton Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
EP1411954B1 (en) 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP2114980B1 (en) 2007-01-12 2012-06-27 BioCryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2155758B1 (en) 2007-05-10 2012-08-22 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer
CN102046626A (zh) 2008-04-23 2011-05-04 吉里德科学公司 用于抗病毒治疗的carba-核苷类似物
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
KR20180006499A (ko) 2009-09-21 2018-01-17 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
PH12013500033A1 (en) 2010-07-19 2017-07-26 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MA34470B1 (fr) 2010-07-22 2013-08-01 Gilead Sciences Inc Procédés et composés pour traiter des infections à virus paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011305652B2 (en) * 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
TW201306841A (zh) 2010-12-20 2013-02-16 Gilead Sciences Inc 治療ｃ型肝炎病毒（ｈｃｖ）之方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
SI2794627T1 (sl) * 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
ME03502B (me) * 2012-03-21 2020-04-20 Janssen Biopharma Inc Supstituisani nukleozidi, nukleotidi i njihovi analozi
GB201220843D0 (en) * 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
EP3013340B9 (en) * 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6562908B2 (ja) * 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
TWI673283B (zh) * 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類

Also Published As

Publication number Publication date
JP2017525699A (ja) 2017-09-07
AU2015305593A1 (en) 2017-02-23
KR20170042643A (ko) 2017-04-19
NZ728707A (en) 2018-06-29
AU2015305593B2 (en) 2018-05-17
AR101561A1 (es) 2016-12-28
TWI673283B (zh) 2019-10-01
CA2958546A1 (en) 2016-02-25
JP2020111608A (ja) 2020-07-27
TW201619178A (zh) 2016-06-01
KR102528928B1 (ko) 2023-05-08
IL250426A0 (en) 2017-03-30
BR112017003242A2 (pt) 2017-11-28
US20190202852A1 (en) 2019-07-04
US20200157137A1 (en) 2020-05-21
US9617295B2 (en) 2017-04-11
US20200087337A1 (en) 2020-03-19
WO2016028866A1 (en) 2016-02-25
CN106573954A (zh) 2017-04-19
CA2958546C (en) 2020-06-23
EP3738969A1 (en) 2020-11-18
EP3183261A1 (en) 2017-06-28
EP3183261B1 (en) 2020-06-17
US20160052953A1 (en) 2016-02-25
US20180340004A1 (en) 2018-11-29
EA201790234A1 (ru) 2017-07-31
US9982006B2 (en) 2018-05-29
SG11201700810SA (en) 2017-03-30
AU2015305593C1 (en) 2018-11-15
US20170327526A1 (en) 2017-11-16
ES2808868T3 (es) 2021-03-02
MX2017002288A (es) 2017-05-22

Similar Documents

Publication Publication Date Title
JP6991188B2 (ja) 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン
JP6765364B2 (ja) ２’−クロロアミノピリミジノンおよびピリミジンジオンヌクレオシド
HK40074916A (en) 4'-substituted-furo[3,2-d]pyrimidine and -pyrrolo[3,2- d]pyrimidine derivatives useful for treating respiratory syncitial virus infections
HK1232547A1 (en) 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides
HK40032020A (en) 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides for use in treating pneumovirinae virus infections
HK1239698A1 (en) 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides
HK1239698B (en) 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides
HK1232857B (zh) 用於治療呼吸道合胞病毒感染的噻吩並[3，2-d]嘧啶、呋喃並[3，2-d]嘧啶和吡咯並[3，2-d]嘧啶
HK1232857A1 (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections
HK1237766B (en) Thieno [3,2-d]pyrimidines, furo [3,2,d]pyrimidines and pyrrolo [3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
HK1237766A1 (en) Thieno [3,2-d]pyrimidines, furo [3,2,d]pyrimidines and pyrrolo [3,2-d]pyrimidines useful for treating respiratory syncitial virus infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200915

R150 Certificate of patent or registration of utility model

Ref document number: 6765364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250